Thursday, Jan. 20, 2022 'Ultrapotent' Antibodies Neutralize SARS-CoV-2 Variants in NIAID Study Caption: This transmission electron micrograph shows a SARS-CoV-2 virus particle (Alpha variant UK B.1.1.7), isolated from a patient sample and cultivated in cell culture. The prominent projections (red) seen on the outside of the virus particle (blue) are spike proteins. Credit: NIAID NIAID scientists have developed an array of monoclonal antibodies from recovered COVID-19 patients, and two of the therapeutic treatments in a recent study neutralized a variety of disease-causing virus variants. The study, not peer reviewed but posted on medRxiv, shows that the monoclonal antibodies have "ultrapotent neutralizing activity" against SARS-CoV-2, the virus that causes COVID-19. One of the treatments, NE12, was effective at neutralizing the original virus strain in the United States, WA-1, as well as the Alpha and Delta variants that emerged. A second treatment, NA8, neutralized the Beta and Omicron variants. The scientists say these types of treatments could play a significant role against newly emerging SARS-CoV-2 variants. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107